Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Long-Term, Multicenter Outcome Study Confirms Clinical Validity and Clinical Utility of Veracyte's Afirma Gene Expression Classifier
South San Francisco, Calif. --- October 23, 2013 --- Data from a new long-term, multicenter study confirm the accuracy of the Afirma Gene Expression Classifier (GEC) in identifying benign thyroid nodule fine needle aspiration (FNA) biopsies among those initially deemed indeterminate, or
View HTML
Toggle Summary Veracyte Presents Preliminary Data Suggesting Potential for an RNA-Based Gene Expression Test to Detect the BRAF V600E Mutation in Thyroid Nodule Biopsy Samples
Findings Presented at 83rd Annual Meeting of the American Thyroid Association
View HTML
Toggle Summary Veracyte, Inc. Files Registration Statement for Initial Public Offering
South San Francisco, Calif. – September 20, 2013 - Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed
View HTML
Toggle Summary Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
South San Francisco, Calif. --- July 8, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the field of molecular cytology, today announced that Aetna, the third largest health plan in the United States, has issued a positive coverage policy for the company’s Afirma Gene
View HTML
Toggle Summary Veracyte Completes $28 Million Series C Financing Round With GE Ventures as a New Investor
South San Francisco, Calif. --- June 28, 2013 --- Veracyte, Inc. , a molecular diagnostics company in the field of molecular cytology, today announced the completion of the final tranche of its $28 million Series C financing. The financing included GE Ventures as a new investor, as well as existing
View HTML
Toggle Summary Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise
South San Francisco, Calif. --- April 17, 2013 --- A new study shows that the number of patients with thyroid nodules who undergo surgery – increasingly to remove all, rather than part, of their thyroid – has risen by 31% over five years, Veracyte announced today.
View HTML
Toggle Summary Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
South San Francisco, Calif. --- April 12, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer. “We are delighted to welcome Shelly Guyer to the Veracyte team,”
View HTML
Toggle Summary Veracyte Announces Results of Study Assessing Use of BRAF Mutation Testing With Its Afirma® Gene Expression Classifier
South San Francisco, Calif. --- March 12, 2013 --- Veracyte, Inc ., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced new study findings showing that when BRAF V600E mutation testing was conducted on ambiguous thyroid nodule samples that were
View HTML
Toggle Summary Veracyte Announces UnitedHealthcare Coverage Policy For the Afirma® Gene Expression Classifier
South San Francisco, Calif. --- March 8, 2013 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that UnitedHealthcare, one of the nation’s largest private health insurers, has issued a positive medical coverage policy for the
View HTML
Toggle Summary New Article in PLOS Currents: Evidence on Genomic Tests Supports Use of Veracyte's Afirma® Gene Expression Classifier to Resolve Ambiguous Thyroid Nodule Biopsies
South San Francisco, Calif. --- February 15, 2013 --- Veracyte, Inc. today announced that a new review article published in PLOS Currents: Evidence on Genomic Tests concludes that published studies and independent assessments and reviews of the Afirma Gene Expression Classifier support the test’s
View HTML